The European Medicines Agency (EMA) has agreed to review a request to approve the investigational CAR T-cell therapy, lisocabtagene maraleucel (liso-cel), for people with pretreated lymphomas. The marketing authorization application, submitted by Bristol Myers Squibb, is specific to patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B), who have tried at least two prior therapies. Liso-cel was granted an accelerated assessment by the EMA, shortening…
You must be logged in to read/download the full post.
The post EMA to Review Liso-cel as CAR T-cell Therapy for Advanced Lymphomas appeared first on BioNewsFeeds.